Does Wegovy Work for Menopause Weight Gain?

Does semaglutide actually reduce the weight that builds during menopause?

The honest answer is: it can help, but it doesn't directly address the hormonal cause. During the menopause transition, falling oestrogen prompts the body to redistribute fat, less from the hips and thighs, more around the abdomen. That shift happens independently of how much someone eats. Semaglutide doesn't change oestrogen levels or reverse that redistribution signal.

What it does do is act on GLP-1 receptors in the brain and gut, reducing appetite, slowing the rate at which the stomach empties, and making it easier to eat less without feeling deprived. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg dose, a figure that came from a broad adult population, not a menopause-specific cohort. No large-scale trial has yet looked at semaglutide exclusively in postmenopausal women, which is a genuine evidence gap.

That said, many women in the menopausal age range were included in the STEP programme, and the overall results suggest the mechanism works regardless of menopausal status. If you want to understand how the treatment fits the specific context of menopause-related weight gain, our page on using Wegovy for menopause weight loss covers the practical considerations in detail. What a prescriber needs to weigh up is whether your broader health picture makes Wegovy appropriate, because the licence covers weight, not the hormonal context around it.

You can read more about the perimenopause angle specifically on our page covering Wegovy for perimenopause weight gain.

Is Wegovy a good fit if you're also on HRT?

This is one of the most practical questions, and it deserves a direct answer. There is no clinical evidence that HRT and semaglutide interact in a way that makes one less effective or less safe. They work through entirely different pathways. Many women use both.

The nuance sits with the form of HRT, not the hormone therapy itself. NHS England's guidance on weight-management injections notes that for tirzepatide (Mounjaro) (not semaglutide) women on oral HRT should consider switching to a transdermal preparation such as a patch or gel, because slowed gastric emptying may reduce absorption of orally-taken preparations. The guidance does not make the same explicit statement about semaglutide, but it is a sensible conversation to have with your GP or gynaecologist before starting, particularly if you are on an oral combined preparation. Transdermal HRT bypasses gut absorption entirely, so it sidesteps the question.

If you want to understand more about how semaglutide works in people without diabetes (the population that includes most menopausal women) our page on how semaglutide works for weight loss in non-diabetics covers the mechanism in plain language.

What does the eligibility check actually look like?

Wegovy is a prescription-only medicine, and the starting point is always a clinical assessment rather than a checklist. The licensed eligibility criteria are a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition, things like high blood pressure, raised cholesterol, obstructive sleep apnoea, or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

Menopause-related weight gain often brings exactly those comorbidities with it, which means many women approaching a prescriber with this concern do qualify. The prescriber's job is to look at the whole picture: your current medicines, your medical history, any contraindications, and what you are hoping to achieve. A quick check you can do right now: measure your waist circumference. The NHS obesity overview explains why waist measurement alongside BMI gives a more complete picture of metabolic risk, and that's worth knowing before any consultation.

At nume, every consultation is read the same day by a GPhC-registered prescriber. A real clinician reviews your answers; there is no automated gatekeeping. You can check your eligibility and start a free consultation here. And if you'd like to understand the broader treatment landscape first, our Wegovy overview is a good place to start.

What's genuinely uncertain, and who should you talk to?

Two things remain honestly unclear. First, whether semaglutide performs differently in postmenopausal women compared with the general trial population, the current data doesn't isolate that group. Second, how Wegovy interacts with the full range of HRT formulations at the individual level. Population data only goes so far.

If you have a history of medullary thyroid carcinoma, MEN2, or active pancreatitis, Wegovy is not appropriate and your prescriber will say so. For a broader safety picture (including what side effects to watch for and when to get medical help) the NHS medicines page for semaglutide is the clearest plain-language reference available. The most important conversation is with someone who knows your full medical history: your GP, your menopause specialist, or a prescriber who can see your complete picture. The relationship between hormones, weight, and appetite is genuinely complex, and a single answer rarely fits everyone.

Women who are pregnant, breastfeeding, or planning to conceive should not use Wegovy. If you are in perimenopause rather than established menopause, the considerations overlap but differ slightly, our page on Wegovy and menopause goes deeper into that distinction, and our perimenopause-specific page covers the earlier transition stage.